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This article describes and compares approved targeted therapies and the newer immunotherapy agents.  
Materials and methods  
This article especially performs an in-depth review of currently available data for tivozanib, explaining its 
mechanism of action, its safety profle and its role as an efcacy drug in the management of renal cancer.   
Results  
Despite the fact that the treatment of advanced RCC has been dramatically modifed in recent years, 
durable remissions are scarce and it remains a lethal disease. For frst- and second-line therapy, there is now 
growing evidence to guide the selection of the appropriate treatment.  
Conclusions  
Several TKIs are standard of care at diferent settings. Among those approved TKIs, tivozanib has similar 
efcacy than others with a better safety profle. The use of prognostic factors is critical to the selection of 
optimal therapy.  
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Introduction 
Renal cancer is one of the most common malignancies worldwide, being 2–3% of all adult 
tumors [1]. Approximately 90% of all renal tumors are renal cell carcinomas (RCC) [2]. 
 
Over the last 2 decades the incidence of RCC increased approximately 2% worldwide [1]. 
However, there has been a parallel improvement in survival, with the advent of antiangiogenic 
drugs, tyrosine kinase inhibitors (TKI), other targeted therapies and immunotherapy [3]. 
Consequently, cytokine-based treatments, such as interferon-α and interleukin-2 (IL-2), which 
were formerly standard-of-care treatment, were quickly abandoned or restricted to very selected 
situations. Several agents targeting the vascular endothelial growth factor (VEGF) pathway 
(sunitinib, bevacizumab, pazopanib, axitinib) or the mammalian target of rapamycin (mTOR) 
pathway (temsirolimus, everolimus) were approved since then progressively approved for first-line 
or later-line use in the treatment of patients with metastatic RCC (mRCC) and became the new 
standard of care [4,5,6,7,8,9]. As a result, the survival of patients with mRCC has significantly 
improved [3]. During last years, the treatment of mRCC has experienced a second revolution with 
the advent of immune checkpoint inhibitors, especially agents targeting the programmed cell 
death-1 (PD-1) receptor as well as with the advent of new-generation TKIs. 
 
This article describes and compares currently approved targeted therapies and the newer 
immunotherapy agents, taking into account that the current approach is focused on selecting the 
most appropriate therapy, based not only in efficacy but also on its safety profile, providing a 
better quality of life for the patients. This article especially performs an in-depth review of one of 
the most recently approved tyrosine kinase inhibitors (TKIs), tivozanib, explaining its mechanism 
of action, its safety profile and its role in the management of mRCC. 
Materials and methods 
A panel of experts convened to review currently available data for tivozanib and its 
comparison versus other approved agents. Evidence acquisition is based on the most recent 
publications of comparative randomized and non-randomized studies as a basis, on moved from 
there by adding ESMO guidelines update from 2018 [10]. 
 
Full electronic searches were performed in the PubMed biomedical literature database using 
medical subject headings (MeSH), a controlled vocabulary thesaurus. The search phrase was 
(((“Carcinoma, Renal Cell”[Mesh]) AND tivozanib)) AND ((second-line) OR first line OR 
(second line)E). Additional searches were carried out in the EMBASE database using the search 
terms: “tivozanib AND AND renal AND cell AND carcinoma”. Conference abstracts published in 
the annual meeting of the American Society of Clinical Oncology (ASCO) and that of the 
European Society for Medical Oncology (ESMO) are included in the EMBASE database. The date 
of the last search was 22 March 2019. 
 
TIVOZANIB: mechanism of action 
VEGF-targeted therapies with TKIs were developed as a result of improved understanding of 
von Hippel–Lindau (VHL) gene mutations leading to the induction of angiogenic protein. VEGF-
TKIs currently approved for mRCC include sunitinib, sorafenib, pazopanib, axitinib, cabozantinib 
and tivozanib [11, 12]. 
 
Tivozanib (Fotivda®, EUSA Pharma, Netherlands) is a new oral multi-targeted TKI that 
potently and selectively blocks all three vascular endothelial growth factor receptors (VEGFR) and 
has been shown to block various VEGF-induced biochemical and biologic responses in vitro, 
including VEGF ligand-induced phosphorylation of all three VEGFR 1, 2 and 3, and proliferation 
of human endothelial cells. The specificity to the VEGFR targets differentiates tivozanib 
hydrochloride from other available TKIs used in mRCC. Among the three VEGFR, VEGFR-2 at 
endothelial cells seem to be the key target [13]. VEGF develops its function mainly by binding to 
endothelial cells and activating VEGFR-2 (also known as KDR) and VEGFR-3 (known as FLT4), 
with a different join affinity for each of these receptors [14]. Hence, the binding of each VEGFR-
TKI activates a different posterior pathway with various results, which lead to tumor proliferation 
by inducing changes within the tumor vasculature and promoting angiogenesis. 
 
The VEGF pathway is a dominant mediator of tumor angiogenesis, which is essential for tumor 
development and growth [15]. By blocking the activation of VEGFR, tivozanib inhibits 
angiogenesis and vascular permeability in tumor tissues, leading to the inhibition of tumor growth. 
VEGFR2 is a major angiogenic receptor which plays a key role in blood vessels homeostasis, 
being involved in cancer progression and metastasis, and is the subtype that is strongly linked to 
inflammatory processes. 
 
A comparison of the potency of VEGFR inhibition for each of the approved TKIs and 
tivozanib, using the maximum inhibitory concentration values reported (IC50) for each VEGFR, 
demonstrated that tivozanib is more potent than sunitinib, pazopanib and sorafenib, with a similar 
potency than axitinib (Fig. 1) [16]. 
 
Non-clinical studies confirmed the anti-tumor activity of tivozanib. These in vivo studies, 
performed on a wide panel of models, including the tumor xenograft models of human RCC, 
demonstrated anti-tumor effects of tivozanib ranging from significant inhibition of the tumor to 
complete regression of the tumor [16]. 
 
VEGFR inhibition by tivozanib is approximately eight times more potent than c-kit inhibition, 
the second most potentially inhibited TKI [17]. 
 
The pharmacokinetics (PK) of tivozanib is similar in subjects with solid tumors compared to 
healthy volunteers. Dosing with food was shown not to have a significant impact on the exposure 
[area under the curve (AUC)] of tivozanib compared to the fasted state [although a reduction in 
maximum concentration (Cmax) was observed], indicating that tivozanib can be administered in 
both the fed and fasted states [18]. 
 
Following a single-dose administration of tivozanib, absorption is rapid with peak plasma 
concentrations occurring at approximately 3 h after administration. However, the absorption 
process is highly variable, probably due to enterohepatic recirculation. Tivozanib is highly bound 
to albumin (>99%) with no concentration dependence over the range 0.1–5 μM and widely 
distributed throughout the body with a volume of distribution (Vz/F) about 100 L. Its half-life 
determined in healthy volunteers is 4.5–5.1 days (108–123 h), longer than sunitinib (40–60 h), 
pazopanib (30.9 h) sorafenib (48 h) and axitinib (2.5–6.1 h) [18]. This long t1/2 allows to 
administer a daily dose reaching serum levels well above the inhibitory concentrations of VEGFR. 




Fig. 1. Relative VEGFR potencies (a) and selectivities (b) for TKIs. Extracted from Pankaj Bhargava and Murray O. 
Robinson’s manuscript “Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status” 
Safety and tolerability studies in subjects with hepatic impairment show that tivozanib was 
eliminated more slowly in subjects with moderate (Child–Pugh Class B) or severe (Child–Pugh 
Class C) hepatic impairment. Tivozanib exposure was increased in patients with severe hepatic 
impairment and in patients with moderate hepatic impairment. No significant increase in exposure 
was observed in patients with mild (Child–Pugh Class A) hepatic impairment. Therefore, no dose 
adjustment is required when administering tivozanib to patients with mild hepatic impairment. 
 
Tivozanib, as opposite to other targeted therapies for mRCC, does not undergo renal excretion, 
hence, it does not require dose adjustment based on creatinine clearance [18]. 
 
Clinical studies with tivozanib were conducted in RCC patients with serum creatinine 
concentration ≤ 2 times the upper limit of normal, including those who may have had a prior 
nephrectomy. Although the impact of further impairment of renal function on the overall 
disposition of tivozanib is unknown, a clinical study has shown that no unchanged tivozanib is 
excreted in the urine indicating that tivozanib does not undergo renal excretion. According to the 
population pharmacokinetic analysis of tivozanib exposure, no dose adjustment is required in 
patients with mild or moderate renal impairment [18]. Clinical experience is limited in patients 
with severe renal impairment. 
 
Tivozanib can be dosed concomitantly with CYP3A4 inhibitors, unlike other approved TKIs. 
 
Results 
Efficacy of first-line treatment for mRCC 
First-line treatment in mRCC has been marked by the use of TKIs. Sunitinib, bevacizumab 
plus interferon and pazopanib showed a benefit in progression-free survival (PFS) in this context 
compared to either interferon, in patients with either good or intermediate or poor prognosis. 
Although the combination bevacizumab plus interferon achieved similar benefits [4, 19], oral TKIs 
were implanted as the standard treatment. 
 
The first TKI that showed activity against interferon-alpha (IFN-α) was sunitinib, in a phase III 
study that included 750 patients with mainly favorable or intermediate prognosis (with up to 6% 
poor prognosis in sunitinib arm versus 7% IFN-α arm) according to Memorial Sloan Katering 
Cancer Center (MSKCC) criteria, and who were randomized to receive sunitinib or IFN-α [20]. 
The main objective of the study was PFS, which was 6 months longer for the sunitinib arm, 11 
versus 5 months (HR 0.42, 95% CI 0.32–0.54; p < 0.001). Secondary objectives included response 
rate (RR), being favorable to sunitinib (31 versus 6%, p < 0.001) and overall survival (OS), which 
was not initially reached. In a subsequent analysis [21], OS was longer in the sunitinib arm (26.4 
versus 21.8 months, HR 0.821, 95% CI 0.673–1.001, p = 0.051) although it did not reach statistical 
significance and RR was 47 versus 12% (p < 0.001) favorable to sunitinib. 
 
Pazopanib was compared to sunitinib in a non-inferiority study (COMPARZ), PFS being the 
main objective in the intention-to-treat population. Primary objective was achieved, PFS being 8.4 
months for pazopanib and 9.5 months for sunitinib (HR 1.05, 95% CI 0.90–1.22). Overall survival 
was not inferior for pazopanib and RR was 33% for the pazopanib arm versus 29% for sunitinib 
arm (p = 0.12). 
 
Tivozanib was compared with sorafenib in the TIVO-1 study, as first- or second-line treatment 
[22]. The study included 517 patients (260 in the tivozanib arm and 257 in the sorafenib arm); 362 
received treatment in the first-line setting. Baseline characteristics were well balanced between 
groups, although tivozanib group had slightly worse conditions (more than 2 metastases locations 
33 versus 25%; MSKCC poor prognosis 7 versus 4%, ECOG 1 55 versus 46%). In each treatment 
arm, around 99% patients had metastatic disease at screening, and around 30% had received a 
prior treatment for metastatic disease. Most patients had intermediate International Metastatic 
Renal Cell Carcinoma Database Consortium (IMDC) prognostic risk (173 patients in tivozanib 
arm; 160 patients in sorafenib arm). 
 
The study showed a favorable benefit to tivozanib in terms of PFS (11.9 versus 9.1 months, HR 
0.797, 95% CI 0.639–0.993, p = 0.042), leading to EMA approval as first-line treatment and hence, 
it was first second-generation TKI approved in this setting. In the subgroup of patients receiving 
first-line treatment (70%), a prespecified analysis showed median PFS was 12.7 months for 
tivozanib versus 9.1 months for sorafenib with a HR of 0.756 (95% CI 0.580–0.985, p = 0.037) 
[23]. 
 
Response rate (RR) was 33.1% for tivozanib (95% CI 27.4–39.2%) versus 23.3% (95% CI 
18.3–29.0%) for sorafenib (p = 0.014). Median duration of response by independent radiology 
review (IRR) was 15.0 months for tivozanib compared to 12.9 months for sorafenib [23]. 
 
Overall survival (OS) showed a favorable trend to sorafenib, although it was not statistically 
significant (29.3 versus 28.8 months, HR 1245, 95% CI 0.954–1.624, p = 0.105). In this study, 
63% of the patients in the sorafenib arm received tivozanib at the time of progression, while only 
13% in the tivozanib arm received a next-line targeted therapy. A formal treatment cross-over was 
not built into the study design; however, patients randomized to sorafenib were given the option of 
crossing over to tivozanib in extension study AV-951-09-902 upon progressive disease (PD). This 
cross-over was potential for confounding and it was concluded that no clear difference in OS has 
been observed between the two treatment groups [23]. 
 
Looking at demographics, there were important differences in terms of geographical regions. 
Post hoc analysis of PFS and OS data was performed on the 186 patients enrolled in North 
America and the European Union (US, Canada, Italy, France, UK, Bulgaria, Czech Republic, 
Romania, Poland, Hungary) to evaluate data by geographical stratification and retain the EU as a 
single region. This analysis revealed a median PFS in the EU/North America region of 12.9 
months versus 7.6 months for sorafenib (p = 0.008) with a HR of 0.597. Additionally, a trend 
towards longer OS in the tivozanib arm (HR 0.503; 95% CI 0.174–1.451; p = 0.195) was observed 
in the group of patients from North America/Western Europe (n = 40) [23]. 
 
Study 902 was a second-line single-arm study designed as an extension study for TIVO-1 
included patients. Patients who developed PD while on prior TKI were crossed over to tivozanib. 
This study reinforced the high efficacy of tivozanib in terms of anti-tumor activity [24]. 
 
Including both studies (TIVO-1 and 902), median PFS by investigator assessment was 14.7 
months for tivozanib compared to 9.7 months for sorafenib patients, p = 0.006, HR 0.755 (95% CI 
0.617–0.922). For the 161 patients who crossed over to tivozanib, ORR was 18.0% (95% CI 
12.4%, 24.8%). Median OS from the start of the first dose was 21.6 months (95% CI 17.0–27.6 
months). For patients who remained on initial randomized tivozanib or sorafenib, the ORR was 
55.7% (95% CI 44.7%, 66.3%) and 57.1% (95% CI 37.2%, 75.5%) respectively [18]. 
 
Cabozantinib was compared to sunitinib in a randomized phase II study (CABOSUN study) 
with 157 included patients of poor (19%) or intermediate risk (81%) according to IMDC criteria 
[25, 26]. Up to 36% patients had bone metastasis. Primary objective was met with an improvement 
in PFS (8.2 versus 5.6 months). The RR was 46% in the cabozantinib arm (95% CI 34–57) versus 
18% (95% CI 10–28) in the sunitinib arm. Median OS was better for cabozantinib although it was 
not statistically significant [26.6 versus 21.2 months for cabozantinib and sunitinib, respectively 
(HR 0.80, 95% CI 0.53–1.21)] [26]. 
 
A retrospective assessment performed by an independent review committee (IRC). This 
analysis resulted in fewer events compared with the previous investigator analysis. Response rate 
with cabozantinib was higher when assessed by the investigator, however, the disease control rate 
with cabozantinib was similar by both assessments. 
 
Cross-study comparisons are confounded by uncontrolled variables in patient characteristics 
and physician practice. The CABOSUN study included a relatively high incidence of patients with 
poor prognostic features not explicitly included in the IMDC criteria, such as the presence of bone 
metastases, greater number of metastatic sites, and worse ECOG PS. 
 
This phase 2 study was designed having a primary endpoint of PFS, and the secondary 
endpoint of OS was not powered to reach survival differences. The observed improvement in PFS 
with cabozantinib compared with sunitinib could be secondary to inhibition of MET and AXL by 
cabozantinib in addition to VEGF receptors. Focusing on the MET status data, 41% were positive 
in cabozantinib arm versus 38% in sunitinib arm. Subgroup analyses of PFS based on MET 
expression level favored cabozantinib over sunitinib regardless of MET status. Although the HR 
more strongly favored cabozantinib for MET-positive versus MET-negative patients, the subgroup 
size was small and analyses were descriptive. 
 
The new immunotherapeutic drugs have also been compared to sunitinib. The CheckMate 214 
study compared the combination of nivolumab (an anti-PD-1 agent) with ipilimumab (anti CTLA-
4) versus sunitinib [27]. A total of 1096 patients were included in this study, in which the co-
primary objectives comprised OS, RR and PFS in patients included with poor or intermediate 
prognosis according to IMDC risk groups and stratified by IMDC 0 versus 1–2 versus 3–6, and 
geographical region. The survival rate at 18 months was 75% in the arm under study compared to 
60% with sunitinib, with a median OS not reached in the combination versus 26.0 months with 
sunitinib (HR 0.63, p < 0.001). The RR was 42% versus 27% favorable to the combination of 
nivolumab and ipilimumab (complete responses 9 versus 1%). The median PFS also favored the 
combination: 11.6 versus 8.4 months (HR 0.82; p = 0.03, not significant by the prespecified 0.009 
threshold). In an update presented in ASCO-GU 2019 [28], the complete RR reached 11%. On the 
other hand, focusing on those patients who had to suspend treatment by protocol [29], it was 
observed that the treatment-free survival was longer in the arm of nivolumab/ipilimumab, with 
survival at 3 years of around 20% in this subgroup. 
 
Several combinations of immunotherapy with TKI have also been compared. Among them, 
results of the KEYNOTE-426 study were recently presented [30], analyzing the combination of 
axitinib–pembrolizumab versus sunitinib, in patients that were stratified by IMDC risk group and 
geographic region; its co-primary objectives included OS and PFS in the ITT population. The 
percentage of patients who were alive at 18 months was 89.9% in the pembrolizumab–axitinib 
group versus 78.3% in the sunitinib group (HR 0.53, 95% CI) 0.38–0.74, p < 0.0001). The median 
PFS was 15.1 versus 11.1 months in favor of the axitinib/pembrolizumab arm (HR 0.69, 95% CI 
0.57–0.84, p < 0.001). The RR also favored the combination: 59.3% versus 35.7% (p < 0.001). In 
addition, the benefit was observed in all risk groups of the IMDC. 
 
Other combinations of immunotherapy and anti-VEGF have also been studied (atezolizumab–
bevacizumab in IMMotion-151, axitinib–avelumab in Javelin Renal 101), although results still 
await further follow-up [31, 32]. IMMotion-151 study showed longer PFS for atezolizumab plus 
bevacizumab versus sunitinib in PD-L1-positive patients with a HR of 0.74 (95% CI 0.57, 0.96), 
with a safety profile consistent with the expected for each of these agents. JAVELIN 101 study 
also showed a PFS benefit in patients harboring PD-L1 expression, with a HR of 0.63 (95% CI 
0.49, 0.81), also assessing other molecular features, such as tumor. There was no relation between 
PFS and TMB. High-angio GES was associated with significantly improved PFS in the sunitinib 
arm but did not lead to benefit in PFS. 
 
TiNivo study assessed tivozanib combined with nivolumab in patients who had not been 
exposed to any of them. This was a phase Ib–II study, including up to 28 patients (6 in dose 
escalation; 22 in dose expansion) [33]. Results are explained in detailed in the following sections. 
 
First-line treatment for mRCC: intermediate risk criteria group analysis 
There are two prognostic models that are used to predict OS in mRCC in the first-line setting: 
Memorial Sloan Kettering Cancer Center (MSKCC) [34], developed for patients treated with 
cytokines, but validated for targeted therapies [35], and the International Metastatic Renal Cell 
Carcinoma Database Consortium (IMDC) [36] for those treated with anti-VEGF. 
 
The MSKCC model [34] uses five clinical and analytical pre-treatment factors (interval 
between diagnosis and treatment, Karnofsky index, hemoglobin levels, calcium and LDH) to 
classify patients as good prognosis (0 risk factors), intermediate (1–2 risk factors) and bad (≥ 3 risk 
factors). The IMDC model [36] uses six pre-treatment clinical and analytical factors (those of the 
MSKCC except LDH plus platelet and neutrophil levels). 
 
Two recent studies with sunitinib as control arm and focused on the population of intermediate 
and poor prognosis have shown benefit for their primary objective, OS, and PFS respectively: a 
phase III study, CheckMate-214 [28], for the combination of nivolumab plus ipilimumab, and a 
randomized phase II study, CABOSUN [26] for cabozantinib. However, in an exploratory analysis 
of the CheckMate-214 study, the sunitinib arm obtained better efficacy results than the 
combination arm in the good prognosis population. 
 
Approximately half of patients diagnosed with mRCC met intermediate prognosis group 
criteria. The discordant results between the population of good and intermediate prognosis in the 
CheckMate-214 study lead us to think, taking into account the heterogeneity of the prognostic 
factors in both classifications, that intermediate risk population could be stratified to better predict 
the efficacy of the available first-line treatments. 
 
At least four retrospective studies have demonstrated differences in OS between patients with 
one and two risk factors [37,38,39,40]. A retrospective analysis of the phase III pivotal study of 
sunitinib versus IFN-α was carried out in the first line of mRCC. Significant differences were 
found for OS among patients with intermediate prognosis with one or two risk factors 
independently of the prognostic model (MSKCC: 23.1 versus 16.7 months and IMDC: 28.2 versus 
16.3 months) [40]. 
 
In the subanalysis of 363 intermediate risk patients of the prospective observational study of 
real-life pazopanib PRINCIPAL [41], it was found that patients could be stratified by number of 
prognostic factors (1 versus 2) to predict with a better security the efficacy results in this 
subpopulation; hence, the heterogeneity of this risk subgroup risk was observed. Median PFS data 
were obtained (13.8 versus 7.4 months and 13.1 versus 8.1 months for MSKCC and IMDC, 
respectively) and OS (NA versus 15.2 and 33.9 versus 19.4 months, respectively) in patients with 
one versus two risk factors. Similar results were obtained when analyzing the population with PS 
(ECOG) < 2 versus ≥ 2, with a PFS of 11.2 versus 5.6 months and 11.8 versus 2.3 months for 
MSKCC and IMDC, respectively and OS of 33.9 versus 9.5 and 5 months, respectively. 
 
This stratification of the intermediate prognostic group may have lost importance after recently 
published results with combinations of axitinib plus pembrolizumab [30] and axitinib plus 
avelumab [32] versus sunitinib in all risk groups, although it allows us to define more accurately 
the prognosis of patients diagnosed with mRCC and make decisions on the first line in those 
patients who are not subsidiary or in whom we do not consider using combinations of anti-VEGF 
and immunotherapy. 
 
Clinical trials design and included populations 
Five pivotal first-line trials design will be analyzed in this section: fase 3 comparing sunitinib 
versus interferon [5], TIVO-1 which compared tivozanib versus sorafenib [23], CheckMate024 
[28], which compared nivolumab plus ipilimumab versus sunitinib, COMPARZ [22], comparing 
pazopanib versus sunitinib, and CABOSUN [26], comparing cabozantinib versus sunitinib. 
 
At the pivotal study of sunitinib [5], 375 patients were recruited in each arm, stratifying the 
patients by the value of serum lactate dehydrogenase (LDH), PS-ECOG and prior nephrectomy. 
The randomization was 1:1. The main objective was PFS and patients had clear cell mRCC. In 
TIVO-1 [23], 517 patients were recruited and stratified by region, number of previous treatments 
and number of metastatic locations. In the CheckMate 024 [28], 1096 patients randomized 1:1 to 
nivolumab–ipilimumab or sunitinib stratified by region and prognostic classification IMDC were 
included, but both in this study and in the CABOSUN [25], phase 2 study with 157 patients who 
were of intermediate or poor prognosis and randomized to cabozantinib or sunitinib, while in the 
other studies all prognostic groups were included. The COMPARZ [22] study randomized 1100 
patients, who were stratified by Karnofsky index, LDH and PS-ECOG, but this phase 3 study had 
a non-inferiority objective. Four of those studies included only naive patients, while in TIVO-1 up 
to 30% of patients in each arm had received at least one previous treatment (interferon, IL2, 
chemotherapy, hormone therapy, chemotherapy or clinical trial). In TIVO-1 and CABOSUN 
studies, patients with stable brain metastases ≥ 3 months were allowed to be included; COMPARZ 
also allowed it, provided they were stable for at least 6 months (see Table 1). 
Table 1 Descriptive comparison among studies                           aPhase 2 study  
 CheckMate214 TIVO-1 COMPARZ SUNITINIB CABOSUNa JAVELIN 101 KEYNOTE‐426 
Treatment Nivolumab–ipilimumab Sunitinib Tivozanib Sorafenib Pazopanib Sunitinib Sunitinib 
Interferon




Sunitinib Pembrolizumab + axitinib Sunitinib 
n N = 550 N = 546 N = 260 N = 257 N = 557 N = 553 N = 375 N = 375 N = 79 N = 78 N = 442 N = 444 N = 432 N = 429 
IMDC IMDC IMDC IMDC Motzer IMDC MSKCC and IMDC: no restriction IMDC 
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prognosis 0 (125 ITT) 
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PFS (p < 0.009), OS 
(p < 0.04), ORR 
(p < 0.001) 
PFS (p < 0.05) Non-inferiority. PFS. 
Analysis ITT 
PFS by ITT PFS, also designed to check 
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MET +  
PFS (blinded central 
review) and OS 
OS and PFS (blinded central 
review) 
Population First line. Intermediate or 
poor prognosis 
First line. Some 




mRCC clear cell first 
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First line. All 
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No brain metastases Brain metastases allowed 
stable 3 months 
Brain metastases 
allowed stable 3 
months 
Excluded symptomatic brain 
metastases 
IK ≥ 70% PS0-1 IK ≥ 70% PS0-1 PS0-2 PS0-1 IK ≥ 70% 
Bone 
metastases 
112 (20%) 119 
(22%) 
61 (23%) 52 (20%) 110 
(20%) 




29 (36.7%) 28 
(35.9%) 
– – – – 
Liver 
metastases 
88 (21%) 89 (21%) 67 (26%) 49 (19%) 86 (15%) 110 
(20%) 
99 (26%) 90 (24%) – – – – – – 
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PD-L1 +: 7.2 months The benefits of 
pembrolizumab plus axitinib 
with respect to overall 
survival and progression-free 
survival were observed in all 
subgroups examined 
HR 0.82, IC95% (0.64–
1.05) p = 0.03 mild-poor 
risk 
HR 0.797 95% CI 
(0.64–0.99), p = 0.042 
HR 1.05 95% CI 
(0.90–1.22) 
HR 0.42 95% CI 
(0.32–0.54), p < 0.001 
HR 0.66 95% CI (0.46–
0.95), p = 0.012 
HR 0.69; 95% CI, 0.56 
to 0.84; p < 0.001 
HR 0.69 (95% CI, 0.57 to 
0.84; p < 0.001 
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HR 0.63 99.8% CI 
(0.44—0.89), p < 0.001 
mild risk group 




13% patients on 
tivozanib received 
further treatment lines 
HR 0.91 95% CI 
(0.76–1.08), p = 0.28 
log rank stratified 
HR 0.821 95% CI 
(0.673–
1.001), p = 0.051 
HR 0.80 95% CI (0.50–
1.26) 
– – 

































59.3% 35.7 % 
p < 0.0001, mild and poor 
risk groups 
p = 0.014 p = 0.03 p < 0.001 – – p < 0.001 
In all these studies, the percentage of nephrectomized patients was high, ranging from 72% in 
CABOSUN to 100% in TIVO-1. Primary objective was PFS for all of them except for the 
CheckMate 024, which had three co-primary objectives: OS (p < 0.04), PFS (p < 0.009) and RR 
(p < 0.001). In the CABOSUN study, a PS-ECOG of 0–2 was allowed, while in the others PS-
ECOG had to be 0–1 for sunitinib versus interferon-alfa and TIVO-1) or Karnofsky index > 70% 
(CheckMate 024 and COMPARZ). 
 
Regarding the statistical design, all had superiority design except for the COMPARZ study, 
that was designed to demonstrate non-inferiority for pazopanib compared to sunitinib and the limit 
for the positive study was the upper limit of the 95% confidence interval. 
 
The characteristics of the patients besides the prognostic classification were similar in most of 
the studies, although with some exceptions, as listed in Table 1. Focusing on liver metastases, all 
studies were well balanced, but TIVO-1 had a higher percentage of patients with liver metastases 
globally; the study with the highest percentage of patients with bone metastases was CABOSUN, 
with 36.7% in the cabozantinib arm and 35.9% in the sunitinib arm, with around 20% in the other 
studies. 
 
The distribution of patients by the prognostic classification of Heng is described in Table 1. In all 
the phase 3 studies, a quality of life analysis was carried out. Figure 2 shows the forest plot for 








Fig. 3 RR for each arm in each of these studies 
Tivozanib safety profile 
The toxicity profile of tivozanib differs, due to its mechanism of action, to other VEFG 
inhibitors, with a lower percentage of toxicities as shown in Table 2. 
 
In the TIVO-1 study, adverse events (AEs) were more frequent for sorafenib arm, mainly due 
to an excess of hand-foot syndrome cases. Additionally, more patients in the sorafenib arm 
underwent either a dose reduction or interruption due to AEs (37.4% versus 11.6%). 
 
However, in the phase III pivotal trial, AEs were more commonly reported for tivozanib (10.8 
versus 5.8%); these AEs were mainly related to progressive disease. Most frequently reported AEs 
in the tivozanib arm included arterial hypertension (44%), diarrhea (23%), dysphonia (21%) and 
fatigue (19%); the most frequent analytical alterations being proteinuria (72%) and ALT (28%), 
AST (37%), amylase (40%) and lipase elevation (46%), anemia (41%), neutropenia (11%), 
thrombocytopenia (18%). The most frequent grade 3–4 AEs were high blood pressure, fatigue and 
elevated lipase. 
 
Hypertension in tivozanib-treated patients was managed with anti-hypertensive medications as 
directed in the study protocols and infrequently led to dose modification; therefore, it was 
considered a manageable risk. 
 
Data show a slightly more favorable safety profile for tivozanib compared with sorafenib in 
terms of lower requirements of dose interruptions. The reduced incidence of hand-foot syndrome 
and diarrhea is an advantage for tivozanib, although counteracted by an increased incidence of 
dysphonia and hypertension. 
 
Another differential aspect of tivozanib lies in the dose intensity as well as in the percentages 
of reductions, interruptions and treatment discontinuations. 
 






Table 2. Most prominent adverse events (appearing in at least 5%) with VEGFR inhibitors 
Agent All grade adverse events 












Creatinine increase 70% 
Thrombocytopenia 68% 
AST increase 56% 
ALT increase 51% 
Sorafenib Diarrhea 48% 
Skin toxicity 41% 
Hand-foot syndrome 33% 
Pazopanib Diarrhea 52% 
Hypertension 40% 
Hair color changes 38% 
ALT and AST increase 53% 
Hyperglycemia 41% 
Bilirubin increase 36% 
Thrombocytopenia 32% 











ALT increase 28% 
AST increase 37% 
Amylase increase 40% 




Cabozantinib Diarrhea 73% 
AST increased 59% 
Fatigue 64% 






Creatinine increased 25% 





Data extracted from Pivotal trials and summary of product characteristics 
Second-line treatment for mRCC 
For the second-line treatment of mRCC, there are several targeted agents available, like TKI or 
mTOR inhibitors. To the already approved second-line options of everolimus, axitinib and 
sorafenib, now we can include the anti-PD-1 inhibitor nivolumab, the VEGFR/cMet inhibitor 
cabozantinib and the VEGFR/FGFR inhibitor lenvatinib combined with the mTOR inhibitor 
everolimus. 
 
Cabozantinib was compared with everolimus in a phase III study (METEOR trial), in patients 
with advanced RCC that had progressed after VEGFR-targeted therapy [42], PFS being the 
primary endpoint. The median PFS was 7.4 months with cabozantinib and 3.8 months with 
everolimus (HR 0.58, 95% CI 0.45–0.75, p < 0.001). The benefit in PFS with cabozantinib was 
observed in all prespecified subgroups regardless of the number of prior VEGFR inhibitors and 
MSKCC prognostic risk category. Importantly, the final mature OS results published 1 year later 
showed an improvement in OS for the first time with a VEGFR inhibitor in advanced RCC [43]. 
The median OS was 21.4 months (95% CI 18.7 to not estimable) with cabozantinib and 16.5 
months (95% CI 14.7–18.8) with everolimus (HR 0.66, 95% CI 0.53–0.83, p = 0.00026). 
 
Regarding the VEGFR/FGFR inhibitor lenvatinib combined with the mTOR inhibitor 
everolimus, recently, the first study to ever show a PFS benefit combining these two drugs was 
published [44]. It was a randomized phase II trial comparing lenvatinib plus everolimus versus 
single-agent lenvatinib or single-agent everolimus as second-line therapy. Lenvatinib is a multi-
TKI of VEGFR-1–3, with inhibitory activity against fibroblast growth factor receptors (FGFR1-4), 
PDGFRα, RET and KIT. Lenvatinib plus everolimus significantly prolonged PFS compared with 
everolimus alone (14.6 versus 5.5 months, HR 0.40, 95% CI 0.24–0.68, p = 0.0005). Single-agent 
lenvatinib also significantly prolonged PFS compared with everolimus alone (HR 0.61, 95% CI 
0.38–0.98; p = 0.048). At the primary data cutoff, OS did not differ significantly between treatment 
arms (median OS of 25.5 months with lenvatinib plus everolimus, versus 17.5 months with single-
agent everolimus). However, in the post hoc updated analysis, the combination resulted in 
extended OS compared with everolimus alone (25.5 versus 15.4 months, HR 0.51, 95% CI 0.30–
0.88; p = 0.024). Despite the small sample size of the study and the tolerability issues, the FDA 
approved the combination of lenvatinib plus everolimus in May 2016 for the treatment of 
advanced RCC following one prior antiangiogenic therapy. EMA subsequently granted approval in 
Europe. 
 
Nivolumab is the first new immunotherapy agent to get regulatory approval for the treatment 
of advanced clear cell RCC. Motzer et al conducted a phase III randomized trial (CheckMate 025 
trial) of nivolumab versus everolimus in advanced clear cell RCC [45]. The primary endpoint was 
OS. The median OS was 25.0 months (95% CI 21.8 to not estimable) with nivolumab and 19.6 
months (95% CI 17.6–23.1) with everolimus (HR 0.73, 98.5% CI 0.57–0.93, p = 0.002). The OS 
benefit was observed irrespective of the MSKCC group and number of prior antiangiogenic 
therapies. Similarly, the benefit with nivolumab over everolimus was seen regardless of PD-L1 
tumor immunohistochemistry expression. The ORR was also significantly greater with nivolumab 
than with everolimus (25% versus 5%; OR 5.98, 95% CI 3.68–9.72, p < 0.001). The median PFS, 
however, was similar in both arms: 4.6 months (95% CI 3.7–5.4) with nivolumab and 4.4 months 
(95%  CI 3.7–5.5) with everolimus (HR 0.88, 95% CI 0.75–1.03, p = 0.11). Nivolumab was better 
tolerated than everolimus, grade 3 or 4 treatment-related AEs occurring in 19% of the patients 
receiving nivolumab as compared with 37% with everolimus. Consequently, in November 2015, 
the FDA approved the use of nivolumab to treat patients with metastatic RCC who have 
previously progressed to one or two regimens of antiangiogenic therapy, becoming a new 
standard-of-care treatment option in that setting. Nivolumab was subsequently EMA-approved for 
RCC in February 2016. 
 
 
Moreover, for the first time in the second-line setting, these three agents were approved based 
on an improvement in OS compared with an active and valid comparator drug such as everolimus. 
Importantly, OS is generally considered as the most relevant surrogate factor of meaningful 
clinical benefit with a given drug. This has led to the most influential international oncology 
guidelines such as the NCCN guidelines [46] and the ESMO guidelines [10] to recommend both 
nivolumab and cabozantinib as the new preferred standard-of-care, second-line options in 
advanced RCC. 
 
Supporting tivozanib use in the second-line setting, extension study (902), provides strong 
evidence of tivozanib in this setting. This study was set up as an open-label extension protocol for 
the pivotal study (AV-951-09-301) and included those patients who received second-line tivozanib 
upon progression to sorafenib control arm. Exclusion criteria included progression of CNS 
metastases, hematological or serum chemistry abnormalities, uncontrolled hypertension and 
treatment with another anti-cancer therapy. 
 
A total of 277 patients were enrolled. Of these, 161 who were initially randomized to sorafenib 
received at least one dose of tivozanib in the extension study. This includes 14 patients who started 
the extension study on sorafenib, 6 of whom had documented PD in the pivotal study. Eighty-eight 
patients who were initially randomized to tivozanib received at least one dose of tivozanib in this 
study. Twenty-eight patients who were initially randomized to sorafenib received at least one dose 
of sorafenib in this study (but did not cross-over to tivozanib). 
 
Median PFS by investigator assessment, including data from the pivotal and extension study 
for the ITT population, was 14.7 months for tivozanib patients compared to 9.7 months for 
sorafenib patients (p = 0.006), HR 0.755 (95% CI 0.617, 0.922). 
 
For the 161 patients who crossed over to tivozanib, ORR was 18.0% (95% CI 12.4%, 24.8%), 
all PR. Median duration of PR was 15.2 months. One hundred and eight patients (67.1%) had PD 
or died during the study; median PFS was 11.0 months (95% CI 7.3–12.7 months). Seventy-eight 
patients (48.4%) died during the study; median OS from the start of the first dose in this study was 
21.6 months (95% CI 17.0–27.6 months). 
 
For patients who remained on initial randomized tivozanib or sorafenib, the ORR was 55.7% 
(95% CI 44.7%, 66.3%) and 57.1% (95% CI 37.2%, 75.5%), respectively. Thirty-five (39.8%) 
patients on tivozanib treatment and one (3.6%) patient on sorafenib treatment had PD or died 
during this study [18]. 
Beyond second line 
As for the third and subsequent treatment line, patients should ideally be assessed whenever 
possible for inclusion in clinical trials. If no clinical trial is available, and due to the absence of 
randomized clinical trials comparing one sequential therapy with another, several possible 
treatment sequences may exist depending on the drugs administered in the first and second line. 
 
Clinical trials in the third-line setting are limited to the GOLD and the RECORD-1 studies. 
Sorafenib can be recommended after a sequence of TKI–mTOR inhibitor, based on the data of the 
GOLD study [47]. Treatment with the mTOR inhibitor everolimus can be given after the sequence 
TKI–TKI, this recommendation being based on a subgroup analysis of the RECORD-1 study [48]. 
 
Most of the targeted therapies have been established in phase III trials that were conducted 
within the same timeframe, so very few were done with comparisons to another agent [49]. 
 
 
Regarding tivozanib in the third-line setting, TIVO-3 was a phase 3 randomized study very 
recently presented at ASCO-GU [50]. It included patients who already failed two or three prior 
systemic regimens, one of which included a VEGFR TKI other than sorafenib or tivozanib; 
patients were stratified based on IMDC risk factors and prior treatment, and then received 
tivozanib or sorafenib. Primary objective was PFS by IRR. Up to 350 patients were enrolled. The 
study was designed with a power of 88% to detect a difference of an increase in 2 months of PFS. 
Both arms were well balanced in terms of baseline characteristics. Up to 40% patients had 
received three prior lines; 60% had two prior lines of therapy. Median PFS was longer in the 
tivozanib arm: 5.6 (95% CI 7.3–5.3) versus 3.9 months (95% CI 5.6–3.7; HR 0.73; p = 0.02). PFS 
rate at 2 years was 18% for tivozanib versus 5% for sorafenib. Patients treated with a prior 
checkpoint inhibitor had a statistically significant benefit with tivozanib (HR 0.55). PFS favored 
tivozanib over sorafenib in most patient subgroups, including either IMDC favorable or 
intermediate, two prior VEGFR-TKIs, prior checkpoint inhibitors and VEGFR-TKI, third and 
fourth line, and regardless of age group [51]. At a median duration on study of 32.5 months, 20 
patients remained progression free on the tivozanib arm compared with 2 patients on the sorafenib 
arm. Median OS was 16.4 months for tivozanib (95% CI 13.4–22.2) and 19.7 months (95% CI 
15.0–24.2) for sorafenib (HR 0.99; 95% CI 0.76–1.29; p = 0.95), according to findings from the 
second prespecified analysis. 
Future treatment options 
As the combination of immunotherapy agents plus targeted therapy is highly interesting, 
TiNivo trial studied the combination of tivozanib plus nivolumab, testing a dose escalation of 
tivozanib with standard doses of nivolumab of 240 mg every 14 days. The combination was found 
safe with a manageable toxicity profile. Patients had an ORR of 56% with a disease control rate of 
96%. Eighteen patients (72%) had tumor shrinkage of at least 25% and one patient had a complete 
response, showing a promising anti-tumor efficacy and a manageable toxicity profile. Up to 15 
patients (60%) experienced at least one grade 3–4 AE, but excluding uncomplicated hypertension, 
treatment-related AE was 44% [33]. 
Discussion 
The field of kidney cancer has surprisingly thrived on targeted therapy. Although new 
advances have improved response rates, OS, and treatment-related toxicities, the treatment 
paradigm continues to evolve [52]. 
 
As the landscape for RCC treatment has been successfully evolving, widely acceptable criteria 
for treatment selection has become needed. Treatment choice should be based not only on 
treatment line and sequence, but also on some molecular histology features including angiogenic 
profile and immunogenic characteristics. Additionally, patients’ profiles including comorbidities 
(making them suitable for immunotherapy) age and risk factor score are key. 
 
The evidence is still somehow limited regarding which the best treatment and sequential 
therapy could be for each group of patients. Sequentiality is not clear at all yet. 
 
The success of future next-generation agents will depend on our ability to select patients most 
likely to respond to treatment. Further studies are needed to inform on the prognostic factors, 
which are critical for the selection of optimal therapy and will be crucial to try to identify those 
patients most likely to get benefit, avoiding unnecessary toxicities in those patients who are 
unlikely to benefit. 
 
 
Several TKIs are standard of care at different settings. As targeted therapies became a 
revolution which positively impacted on survival, now quality of life is a key objective. TKIs 
monotherapy improve survival with very well-manageable AEs, hence, every effort should be 
directed to identify which patients may have more benefit by receiving TKIs in the first line. 
Probably good prognostic patients or those patients with only one risk factor may get the strongest 
benefit with this treatment sequencing, rather than receiving upfront immunotherapy followed by 
TKIs. TKI followed by PD-1 inhibitor drugs is an approach that could be considered only after 
assessing thoroughly the patient’s profile and risk factors. 
 
Among those approved TKIs, tivozanib has similar efficacy with a better safety profile and a 
more comfortable posology, being administered for 3 weeks every 4 weeks, which decreases 
indirect costs. Renal function should be taken into account, as tivozanib does not have urinary 
excretion and may be administered in patients with mildly limited creatinine clearance. 
 
Toxicities appear usually during first cycles with TKIs and, once managed, they usually do not 
reappear and do not usually lead to a dose reduction or interruption. Toxicities also impact on 
global cost of treatment, which is dramatically different among treatments (especially for new 
emerging drugs and combinations); this also supports the importance of a carefully performed, 
based on patients’ profiles, regimen selection. 
 
There is a group of patients, without any risk factor, who get the most important benefit from 
TKIs and can be considered as “long survivors”, reaching median overall survival over 40 months 
[52]. This encourages us to look for robust predictive prognosis criteria to identify this population. 
 
Biomarkers studies are needed to improve the knowledge about those which are related to 
angiogenesis and their PD-L1 expression. Probably PD-L1 expression plus prognostic score index 
will be studied to be validated to predict which patients may get better benefit. There was a recent 
study correlating the IMDC prognostic score at start of systemic therapy with RNA expression of 
genes involved in angiogenesis and in the immunosuppressive microenvironment. The majority of 
IMDC good-risk RCC patients had clear cell RCC (CCRCC)-2 tumors (classical subtype 
according to molecular characteristics), displaying a higher expression of the VEGF-dependent 
proangiogenic pathway. Molecular subtypes range from 1–4, depending mainly on transcriptome 
and methylome profiles. These molecular profiles may be supportive to predict response, PFS and 
OS in patients treated with TKIs [11]. This actually may explain the increased benefit of sunitinib 
versus ipilimumab–nivolumab in good risk patients in CheckMate214 [53]. Therefore, with 
combined ipilimumab–nivolumab, some patients may be overtreated. 
 
As a predictive and prognostic factor, immune microenvironment in mRCC is key to 
understand its response to targeted treatments. T-cell exhaustion/inhibition plays an important role 
in mRCC pathogenesis. It has been described that the density of PD-1 + cells and the tumor 
expression of PD-L1 are associated with a poor clinical outcome in patients treated with anti-PD-
1/anti-PD-L1 therapy [54]. 
 
Tumors with high inflammatory immune infiltrate have a high expression of PD-1 and its 
ligands, and correlate with the worst prognosis. Indeed, this inflammatory/proangiogenic profile 
may contribute to local immunosuppression process. 
 
Immune profiles should guide the selection of suitable patients to receive immunotherapies and 
need to be further validated in larger and independent cohorts. 
 
There is a sound rationale for biomarkers to be incorporated into clinical research to improve 
the current knowledge. Additionally, data in real-life patients are also essential to improve the 
knowledge regarding efficacy and toxicity of tivozanib, in combination with tumor 
microenviroment data. 
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